NuVasive, Inc. (NUVA): Price and Financial Metrics

NuVasive, Inc. (NUVA)

Today's Latest Price: $43.51 USD

1.47 (-3.27%)

Updated Apr 3 12:00am

Add NUVA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

NUVA Stock Summary

  • With a market capitalization of $2,456,730,156, Nuvasive Inc has a greater market value than 72.52% of US stocks.
  • With a price/earnings ratio of 37.66, Nuvasive Inc P/E ratio is greater than that of about 86.93% of stocks in our set with positive earnings.
  • Over the past twelve months, NUVA has reported earnings growth of 155.56%, putting it ahead of 92.42% of US stocks in our set.
  • Stocks that are quantitatively similar to NUVA, based on their financial statements, market capitalization, and price volatility, are HAE, MTRN, TNC, MTSC, and KAI.
  • NUVA's SEC filings can be seen here. And to visit Nuvasive Inc's official web site, go to
NUVA Daily Price Range
NUVA 52-Week Price Range

NUVA Stock Price Chart More Charts

NUVA Price/Volume Stats

Current price $43.51 52-week high $81.91
Prev. close $44.98 52-week low $28.55
Day low $42.98 Volume 721,500
Day high $45.72 Avg. volume 985,648
50-day MA $62.18 Dividend yield N/A
200-day MA $66.06 Market Cap 2.27B

NuVasive, Inc. (NUVA) Company Bio

NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.

NUVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Nuvasive Inc. To summarize, we found that Nuvasive Inc ranked in the 34th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Nuvasive Inc ended up being:

  • The company's compound free cash flow growth rate over the past 5.56 years comes in at 0.12%; that's greater than 52.47% of US stocks we're applying DCF forecasting to.
  • 77% of the company's capital comes from equity, which is greater than 61.64% of stocks in our cash flow based forecasting set.
  • The weighted average cost of capital for the company is 7. This value is greater than only 23.58% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NUVA, try ENTA, BHC, NVS, USPH, and IQV.

NUVA Latest News Stream

Event/TimeNews Detail
Loading, please wait...

NUVA Latest Social Stream

Loading social stream, please wait...

View Full NUVA Social Stream

NUVA Price Returns

1-mo -29.98%
3-mo -43.85%
6-mo -32.84%
1-year -24.30%
3-year -40.22%
5-year 2.59%
YTD -43.74%
2019 56.05%
2018 -15.27%
2017 -13.17%
2016 24.49%
2015 14.74%

Continue Researching NUVA

Here are a few links from around the web to help you further your research on Nuvasive Inc's stock as an investment opportunity:

Nuvasive Inc (NUVA) Stock Price | Nasdaq
Nuvasive Inc (NUVA) Stock Quote, History and News - Yahoo Finance
Nuvasive Inc (NUVA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7349 seconds.